Pattern of disease progression following stereotactic radiosurgery in malignant glioma patients

[1]  Xiang Liu,et al.  Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region. , 2020, Journal of neurosurgery.

[2]  D. Silbergeld,et al.  Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. , 2019, Neurosurgery.

[3]  G. Barnett,et al.  Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. , 2019, Journal of neurosurgery.

[4]  In-Hee Lee,et al.  Spatiotemporal genomic architecture informs precision oncology in glioblastoma , 2017, Nature Genetics.

[5]  E. Chang,et al.  Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience , 2016, Neurosurgery.

[6]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[7]  Kenneth Hess,et al.  The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? , 2016, Journal of neurosurgery.

[8]  D. Kondziolka,et al.  Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. , 2015, Journal of neurosurgery.

[9]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[10]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[11]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[12]  C. Drake,et al.  Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses , 2013, BioMed research international.

[13]  B. Jones,et al.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. , 2013, The British journal of radiology.

[14]  M. Mehta,et al.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. , 2011, Current cancer therapy reviews.

[15]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Carol Walker,et al.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. , 2006, Brain : a journal of neurology.

[17]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[19]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G S Bauman,et al.  Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.

[21]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[22]  I. Gibbs,et al.  Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. , 2018, Neurosurgery.

[23]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[24]  M. Chamberlain.  Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.